+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Endocrine Testing Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2019-2029F

  • PDF Icon

    Report

  • 182 Pages
  • February 2024
  • Region: Global
  • TechSci Research
  • ID: 5941855
Free Webex Call
10% Free customization
Free Webex Call

Speak directly to the analyst to clarify any post sales queries you may have.

10% Free customization

This report comes with 10% free customization, enabling you to add data that meets your specific business needs.

Global Endocrine Testing Market was valued at USD 11.52 Billion in 2023 and is anticipated to project impressive growth in the forecast period with a CAGR of 8.25% through 2029. The global healthcare industry is witnessing a significant shift towards personalized medicine and precision diagnostics. One of the key components of this transformation is endocrine testing, which plays a crucial role in understanding and diagnosing hormonal imbalances and related disorders. The global endocrine testing market has been growing steadily, driven by factors such as an aging population, increasing prevalence of endocrine disorders, advancements in diagnostic technologies, and a growing awareness of the importance of early disease detection. Endocrine testing involves the assessment of hormone levels in the body to diagnose various conditions, including thyroid disorders, diabetes, adrenal diseases, and hormonal imbalances. The global endocrine testing market encompasses a wide range of tests, such as blood tests, urine tests, saliva tests, and imaging studies. These tests are performed in clinical laboratories, hospitals, and point-of-care settings, making them readily accessible to patients worldwide. The increasing incidence of endocrine disorders, such as diabetes, thyroid diseases, and hormonal imbalances, is a major driver of the market. Changing lifestyles, environmental factors, and genetic predispositions contribute to the growing burden of these diseases. With the global population aging, the demand for endocrine testing is increasing, as older individuals are more prone to endocrine disorders and related complications. Ongoing advancements in diagnostic technologies, including immunoassays, liquid chromatography-mass spectrometry (LC-MS), and molecular diagnostic techniques, have improved the accuracy and efficiency of endocrine testing. Increased awareness of the importance of early detection and routine screening for endocrine disorders has encouraged individuals to seek testing and physicians to prescribe these tests.

Key Market Drivers

Rising Incidence of Endocrine Disorders is Driving the Global Endocrine Testing Market

The global endocrine testing market is witnessing significant growth, driven by the rising incidence of endocrine disorders. Endocrine disorders affect the endocrine system, a network of glands that secrete hormones to regulate various bodily functions. These disorders can have a profound impact on an individual's health and well-being. The prevalence of endocrine disorders is on the rise, and this has led to an increased demand for endocrine testing, diagnosis, and management. Endocrine disorders are conditions that disrupt the normal functioning of the endocrine system, which includes glands like the thyroid, adrenal, pancreas, and pituitary. Hormones produced by these glands play a crucial role in regulating metabolism, growth, mood, energy levels, and various other bodily functions. When the endocrine system malfunctions, it can lead to various disorders, such as diabetes, thyroid disorders, adrenal dysfunction, and hormonal imbalances.

Modern lifestyles, characterized by sedentary behavior, unhealthy diets, and stress, contribute to the development of endocrine disorders such as obesity and type 2 diabetes. Exposure to environmental toxins and pollutants can disrupt the endocrine system, leading to hormonal imbalances. As the global population ages, the prevalence of age-related endocrine disorders, like osteoporosis and hormone deficiencies, is increasing. Some endocrine disorders have a genetic component, and individuals with a family history of these conditions are at a higher risk. Endocrine testing plays a crucial role in the early detection and management of endocrine disorders. Timely diagnosis can lead to more effective treatment and improved patient outcomes. It allows healthcare professionals to assess hormone levels, identify abnormalities, and develop personalized treatment plans. Common endocrine tests include blood tests for hormone levels, imaging studies, and stimulation or suppression tests to assess hormone production and regulation.

Growing awareness about the importance of early detection and management of endocrine disorders among both healthcare providers and patients is driving the demand for endocrine testing. Advances in medical technology, including more accurate and efficient testing methods, are making it easier to diagnose and monitor endocrine disorders. The aging global population is creating a substantial market for endocrine testing, as age-related endocrine disorders become more prevalent. Developing countries are investing in healthcare infrastructure, making endocrine testing more accessible to a larger population. Ongoing research in endocrinology is leading to the development of new tests and diagnostic tools, further propelling market growth.

Expanding Healthcare Infrastructure is Driving the Global Endocrine Testing Market

Expanding healthcare infrastructure is playing a pivotal role in driving the growth of the global endocrine testing market. Endocrine testing refers to the process of assessing the functionality of the endocrine system, which is responsible for regulating various physiological processes in the human body through the production and secretion of hormones. These tests are crucial for diagnosing and managing a wide range of endocrine disorders, such as diabetes, thyroid dysfunction, adrenal disorders, and hormonal imbalances. Advances in medical technology have led to the development of more accurate and efficient endocrine testing methods. These innovations have made it easier for healthcare facilities to conduct tests, interpret results, and provide timely interventions. Moreover, the integration of automation and information technology in healthcare has streamlined the testing process. Many countries are increasing their healthcare investments to meet the growing demands of their populations. This includes funding for the expansion and modernization of healthcare infrastructure, which encompasses diagnostic laboratories and clinics that offer endocrine testing services.

Improved healthcare infrastructure means that healthcare services, including endocrine testing, are more accessible to a larger portion of the population. Increased access encourages individuals to undergo regular check-ups and testing, which is essential for early disease detection and management. With expanding healthcare infrastructure, there is a greater emphasis on preventive healthcare measures. Endocrine testing is not only used for diagnosing diseases but also for screening individuals at risk, allowing healthcare providers to take proactive measures to prevent the onset of endocrine disorders. As the global population ages, the incidence of endocrine disorders, such as diabetes and hormonal imbalances, is expected to increase. Expanding healthcare infrastructure is crucial to meet the healthcare needs of this aging demographic, which often requires regular endocrine monitoring and management. Expanding healthcare infrastructure often comes hand in hand with health education and awareness programs. As people become more aware of the importance of regular health check-ups and early disease detection, the demand for endocrine testing services is likely to rise.

Key Market Challenges

Complex Regulatory Landscape

One of the foremost challenges in the endocrine testing market is the complex and evolving regulatory landscape. Different countries have varying regulations governing the approval and use of diagnostic tests. Ensuring that products meet these requirements can be a time-consuming and costly process. The need for standardized, harmonized regulations that facilitate global access to innovative endocrine testing methods is apparent.

Rapid Technological Advancements

The rapid pace of technological advancements poses both opportunities and challenges for the endocrine testing market. While technological innovations enable more accurate and efficient testing, they also lead to the constant need for research and development, which can be expensive and time-consuming. Moreover, the industry must ensure that new technologies adhere to quality standards and are accessible to healthcare providers worldwide.

Expanding Knowledge of Endocrinology

Our understanding of endocrinology is continually evolving, with new hormones, biomarkers, and interconnections being discovered. As a result, endocrine testing methods need to adapt and expand to accommodate this growing body of knowledge. Ensuring that healthcare professionals are aware of these advancements and are proficient in their application is a significant challenge.

Cost and Accessibility

Endocrine testing can be expensive, and the cost can act as a barrier to accessing necessary diagnostic services. This is particularly relevant in low- and middle-income countries where healthcare resources are limited. Overcoming this challenge involves developing cost-effective testing methods and increasing accessibility to these services, even in resource-constrained settings.

Data Security and Privacy

With the increasing use of electronic health records and digital platforms, the endocrine testing market faces significant challenges related to data security and patient privacy. The industry must continuously invest in robust cybersecurity measures to protect sensitive patient information and maintain trust in the healthcare system.

Labor Shortages

The endocrine testing market heavily relies on skilled professionals, such as endocrinologists, laboratory technicians, and pathologists. However, there is a growing shortage of these experts, particularly in some regions. This shortage can impact the speed and quality of endocrine testing services, requiring investments in training and recruitment.

Patient Education and Awareness

Many individuals remain unaware of the significance of endocrine testing and the role hormones play in overall health. This lack of awareness can lead to delayed diagnoses and underutilization of endocrine testing services. Overcoming this challenge involves extensive public education campaigns and awareness programs.

Key Market Trends

Technological Advancements

Technological advancements have consistently reshaped the landscape of healthcare, particularly in the field of diagnostic testing. The global endocrine testing market, in particular, is experiencing a significant surge due to the integration of cutting-edge technologies. As our understanding of endocrinology grows, so too does the demand for more precise, efficient, and accessible endocrine tests. One of the key drivers of the global endocrine testing market is the discovery of novel biomarkers enabled by advancements in proteomics, genomics, and metabolomics. These techniques allow researchers to identify and measure previously undiscovered hormones and metabolic markers. This not only enhances our understanding of the endocrine system but also leads to more comprehensive and specific diagnostic tests.

Immunoassays have been revolutionized with the development of highly sensitive and specific immunoassay technologies. Additionally, mass spectrometry techniques have allowed for more precise quantification of hormones and metabolites in the blood, further improving the accuracy of endocrine testing. The demand for rapid and convenient diagnostic tests is on the rise. Point-of-Care Testing (POCT) devices, including handheld hormone analyzers, have been developed to provide near-instant results, reducing the time between testing and diagnosis. This technology is particularly beneficial in emergency settings and for managing chronic endocrine disorders. AI and machine learning algorithms are being integrated into endocrine testing processes. These technologies can assist in data interpretation, enhance diagnostic accuracy, and identify subtle patterns that may be challenging for human analysis. AI also aids in predicting disease progression and personalizing treatment plans.

The growth of telemedicine has expanded the reach of endocrine testing. Patients can access diagnostic tests from the comfort of their homes and consult with healthcare providers remotely. This has become especially important during the COVID-19 pandemic, and it's likely to remain an integral part of healthcare in the post-pandemic world. The global endocrine testing market is experiencing rapid expansion, driven by technological advancements and an increased understanding of the endocrine system. These innovations result in more accurate, rapid, and accessible diagnostic tests, which are essential for managing endocrine disorders effectively. As technology continues to evolve, the future of endocrine testing holds promising possibilities for improved patient care and outcomes, making it an exciting and dynamic field within the broader healthcare landscape.

Segmental Insights

Technology Insight

Based on the category of test type, Thyroid Stimulating Hormone (TSH) Test emerged as the dominant player in the global market for Endocrine Testing in 2023. TSH testing is an essential diagnostic tool for evaluating thyroid function. When the thyroid gland is underactive (hypothyroidism) or overactive (hyperthyroidism), TSH levels are often the first to show significant changes. High TSH levels typically indicate an underactive thyroid, while low TSH levels suggest an overactive thyroid. Monitoring TSH levels allows healthcare professionals to diagnose thyroid disorders accurately and tailor treatment plans accordingly. TSH testing's dominance is also attributed to the increasing adoption of routine thyroid screening, especially among high-risk groups. Many healthcare providers recommend thyroid function tests as part of their annual check-up protocols. Routine screening helps detect thyroid disorders at an early stage, enabling prompt intervention and improved patient outcomes.

Advancements in laboratory testing techniques have made TSH testing more accurate and accessible. High-sensitivity TSH assays have been developed, allowing for the detection of subtle variations in TSH levels. These advancements have enabled healthcare professionals to diagnose thyroid disorders with greater precision. The availability of point-of-care TSH testing has further contributed to its dominance. Point-of-care testing allows for rapid and convenient TSH measurements, reducing the time and inconvenience associated with traditional laboratory tests. Patients and healthcare providers can receive results quickly, leading to quicker diagnosis and treatment initiation.

Technology Insights

The Tandem Mass Spectrometry segment is projected to experience rapid growth during the forecast period. Tandem Mass Spectrometry (MS/MS) has emerged as a game-changer in the field of endocrine testing. It is a highly sensitive and specific analytical technique that allows for the simultaneous measurement of multiple hormones and metabolites in a single sample. MS/MS works by ionizing and separating molecules based on their mass-to-charge ratio, followed by the detection of the resulting ions. In the context of endocrine testing, MS/MS enables the precise quantification of hormones and metabolites at very low concentrations.

MS/MS can detect hormones at extremely low concentrations, making it particularly valuable for diagnosing disorders characterized by subtle hormonal imbalances. MS/MS allows for the simultaneous measurement of multiple analytes in a single sample, providing a comprehensive overview of the patient's endocrine profile. MS/MS can distinguish between closely related molecules, reducing the risk of false positives and false negatives. Unlike some other methods, MS/MS provides accurate and precise quantification of analytes, making it suitable for monitoring hormone levels over time.

Regional Insights

North America emerged as the dominant player in the global Endocrine Testing market in 2023, holding the largest market share in terms of value. North America has a history of innovation in the field of healthcare, with numerous research institutions and companies dedicated to developing state-of-the-art diagnostic tools. The region consistently invests in advanced technologies for endocrine testing, making it a leader in cutting-edge assays and equipment. The region faces a higher prevalence of endocrine disorders due to various factors, including lifestyle changes and dietary habits. This increased burden has necessitated a greater emphasis on endocrine testing, fostering growth in the sector.

Report Scope:

In this report, the Global Endocrine Testing Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Endocrine Testing Market, By Test Type:

  • Estradiol (E2) Test
  • Follicle Stimulating Hormone (FSH) Test
  • Human Chorionic Gonadotropin (hCG) Hormone Test
  • Luteinizing Hormone (LH) Test
  • Dehydroepiandrosterone Sulfate (DHEAS) Test
  • Progesterone Test
  • Testosterone Test
  • Thyroid Stimulating Hormone (TSH) Test
  • Prolactin Test
  • Cortisol Test
  • Insulin Test
  • Others

Endocrine Testing Market, By Technology:

  • Tandem Mass Spectrometry
  • Immunoassay
  • Monoclonal & Polyclonal Antibody Technologies
  • Sensor Technology
  • Clinical Chemistry
  • Others

Endocrine Testing Market, By End Use:

  • Hospitals & Clinics
  • Ambulatory Care Centers
  • Others

Endocrine Testing Market, By Region:

  • North America
  • United States
  • Canada
  • Mexico
  • Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
  • Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
  • South America
  • Brazil
  • Argentina
  • Colombia
  • Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Endocrine Testing Market.

Available Customizations:

Global Endocrine Testing market report with the given market data, the publisher offers customizations according to a company's specific needs.


This product will be delivered within 1-3 business days.

Table of Contents

1. Product Overview
1.1. Market Definition
1.2. Scope of the Market
1.2.1. Markets Covered
1.2.2. Years Considered for Study
1.2.3. Key Market Segmentations
2. Research Methodology
2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations
3. Executive Summary
3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends
4. Global Endocrine Testing Market Outlook
4.1. Market Size & Forecast
4.1.1. By Value
4.2. Market Share & Forecast
4.2.1. By Test Type (Estradiol (E2) Test, Follicle Stimulating Hormone (FSH) Test, Human Chorionic Gonadotropin (hCG) Hormone Test, Luteinizing Hormone (LH) Test, Dehydroepiandrosterone Sulfate (DHEAS) Test, Progesterone Test, Testosterone Test, Thyroid Stimulating Hormone (TSH) Test, Prolactin Test, Cortisol Test, Insulin Test, Others)
4.2.2. By Technology (Tandem Mass Spectrometry, Immunoassay, Monoclonal & Polyclonal Antibody Technologies, Sensor Technology, Clinical Chemistry, Others)
4.2.3. By End use (Hospitals & Clinics, Ambulatory Care Centers, Others)
4.2.4. By Region
4.2.5. By Company (2023)
4.3. Market Map
4.3.1. By Test Type
4.3.2. By Technology
4.3.3. By End use
4.3.4. By Region
5. Asia Pacific Endocrine Testing Market Outlook
5.1. Market Size & Forecast
5.1.1. By Value
5.2. Market Share & Forecast
5.2.1. By Test Type
5.2.2. By Technology
5.2.3. By End use
5.2.4. By Country
5.3. Asia Pacific: Country Analysis
5.3.1. China Endocrine Testing Market Outlook
5.3.1.1. Market Size & Forecast
5.3.1.1.1. By Value
5.3.1.2. Market Share & Forecast
5.3.1.2.1. By Test Type
5.3.1.2.2. By Technology
5.3.1.2.3. By End use
5.3.2. India Endocrine Testing Market Outlook
5.3.2.1. Market Size & Forecast
5.3.2.1.1. By Value
5.3.2.2. Market Share & Forecast
5.3.2.2.1. By Test Type
5.3.2.2.2. By Technology
5.3.2.2.3. By End use
5.3.3. Australia Endocrine Testing Market Outlook
5.3.3.1. Market Size & Forecast
5.3.3.1.1. By Value
5.3.3.2. Market Share & Forecast
5.3.3.2.1. By Test Type
5.3.3.2.2. By Technology
5.3.3.2.3. By End use
5.3.4. Japan Endocrine Testing Market Outlook
5.3.4.1. Market Size & Forecast
5.3.4.1.1. By Value
5.3.4.2. Market Share & Forecast
5.3.4.2.1. By Test Type
5.3.4.2.2. By Technology
5.3.4.2.3. By End use
5.3.5. South Korea Endocrine Testing Market Outlook
5.3.5.1. Market Size & Forecast
5.3.5.1.1. By Value
5.3.5.2. Market Share & Forecast
5.3.5.2.1. By Test Type
5.3.5.2.2. By Technology
5.3.5.2.3. By End use
6. Europe Endocrine Testing Market Outlook
6.1. Market Size & Forecast
6.1.1. By Value
6.2. Market Share & Forecast
6.2.1. By Test Type
6.2.2. By Technology
6.2.3. By End use
6.2.4. By Country
6.3. Europe: Country Analysis
6.3.1. France Endocrine Testing Market Outlook
6.3.1.1. Market Size & Forecast
6.3.1.1.1. By Value
6.3.1.2. Market Share & Forecast
6.3.1.2.1. By Test Type
6.3.1.2.2. By Technology
6.3.1.2.3. By End use
6.3.2. Germany Endocrine Testing Market Outlook
6.3.2.1. Market Size & Forecast
6.3.2.1.1. By Value
6.3.2.2. Market Share & Forecast
6.3.2.2.1. By Test Type
6.3.2.2.2. By Technology
6.3.2.2.3. By End use
6.3.3. Spain Endocrine Testing Market Outlook
6.3.3.1. Market Size & Forecast
6.3.3.1.1. By Value
6.3.3.2. Market Share & Forecast
6.3.3.2.1. By Test Type
6.3.3.2.2. By Technology
6.3.3.2.3. By End use
6.3.4. Italy Endocrine Testing Market Outlook
6.3.4.1. Market Size & Forecast
6.3.4.1.1. By Value
6.3.4.2. Market Share & Forecast
6.3.4.2.1. By Test Type
6.3.4.2.2. By Technology
6.3.4.2.3. By End use
6.3.5. United Kingdom Endocrine Testing Market Outlook
6.3.5.1. Market Size & Forecast
6.3.5.1.1. By Value
6.3.5.2. Market Share & Forecast
6.3.5.2.1. By Test Type
6.3.5.2.2. By Technology
6.3.5.2.3. By End use
7. North America Endocrine Testing Market Outlook
7.1. Market Size & Forecast
7.1.1. By Value
7.2. Market Share & Forecast
7.2.1. By Test Type
7.2.2. By Technology
7.2.3. By End use
7.2.4. By Country
7.3. North America: Country Analysis
7.3.1. United States Endocrine Testing Market Outlook
7.3.1.1. Market Size & Forecast
7.3.1.1.1. By Value
7.3.1.2. Market Share & Forecast
7.3.1.2.1. By Test Type
7.3.1.2.2. By Technology
7.3.1.2.3. By End use
7.3.2. Mexico Endocrine Testing Market Outlook
7.3.2.1. Market Size & Forecast
7.3.2.1.1. By Value
7.3.2.2. Market Share & Forecast
7.3.2.2.1. By Test Type
7.3.2.2.2. By Technology
7.3.2.2.3. By End use
7.3.3. Canada Endocrine Testing Market Outlook
7.3.3.1. Market Size & Forecast
7.3.3.1.1. By Value
7.3.3.2. Market Share & Forecast
7.3.3.2.1. By Test Type
7.3.3.2.2. By Technology
7.3.3.2.3. By End use
8. South America Endocrine Testing Market Outlook
8.1. Market Size & Forecast
8.1.1. By Value
8.2. Market Share & Forecast
8.2.1. By Test Type
8.2.2. By Technology
8.2.3. By End use
8.2.4. By Country
8.3. South America: Country Analysis
8.3.1. Brazil Endocrine Testing Market Outlook
8.3.1.1. Market Size & Forecast
8.3.1.1.1. By Value
8.3.1.2. Market Share & Forecast
8.3.1.2.1. By Test Type
8.3.1.2.2. By Technology
8.3.1.2.3. By End use
8.3.2. Argentina Endocrine Testing Market Outlook
8.3.2.1. Market Size & Forecast
8.3.2.1.1. By Value
8.3.2.2. Market Share & Forecast
8.3.2.2.1. By Test Type
8.3.2.2.2. By Technology
8.3.2.2.3. By End use
8.3.3. Colombia Endocrine Testing Market Outlook
8.3.3.1. Market Size & Forecast
8.3.3.1.1. By Value
8.3.3.2. Market Share & Forecast
8.3.3.2.1. By Test Type
8.3.3.2.2. By Technology
8.3.3.2.3. By End use
9. Middle East and Africa Endocrine Testing Market Outlook
9.1. Market Size & Forecast
9.1.1. By Value
9.2. Market Share & Forecast
9.2.1. By Test Type
9.2.2. By Technology
9.2.3. By End use
9.2.4. By Country
9.3. MEA: Country Analysis
9.3.1. South Africa Endocrine Testing Market Outlook
9.3.1.1. Market Size & Forecast
9.3.1.1.1. By Value
9.3.1.2. Market Share & Forecast
9.3.1.2.1. By Test Type
9.3.1.2.2. By Technology
9.3.1.2.3. By End use
9.3.2. Saudi Arabia Endocrine Testing Market Outlook
9.3.2.1. Market Size & Forecast
9.3.2.1.1. By Value
9.3.2.2. Market Share & Forecast
9.3.2.2.1. By Test Type
9.3.2.2.2. By Technology
9.3.2.2.3. By End use
9.3.3. UAE Endocrine Testing Market Outlook
9.3.3.1. Market Size & Forecast
9.3.3.1.1. By Value
9.3.3.2. Market Share & Forecast
9.3.3.2.1. By Test Type
9.3.3.2.2. By Technology
9.3.3.2.3. By End use
9.3.4. Egypt Endocrine Testing Market Outlook
9.3.4.1. Market Size & Forecast
9.3.4.1.1. By Value
9.3.4.2. Market Share & Forecast
9.3.4.2.1. By Test Type
9.3.4.2.2. By Technology
9.3.4.2.3. By End use
10. Market Dynamics
10.1. Drivers
10.2. Challenges
11. Market Trends & Developments
11.1. Recent Developments
11.2. Product Launches
11.3. Mergers & Acquisitions
12. Global Endocrine Testing Market: SWOT Analysis
13. Porter’s Five Forces Analysis
13.1. Competition in the Industry
13.2. Potential of New Entrants
13.3. Power of Suppliers
13.4. Power of Customers
13.5. Threat of Substitute Product
14. Competitive Landscape
14.1. Abbott Laboratories
14.1.1. Business Overview
14.1.2. Company Snapshot
14.1.3. Product & Services
14.1.4. Financials (In case of listed)
14.1.5. Recent Developments
14.1.6. SWOT Analysis
14.2. AB Sciex Corporation
14.3. Agilent Technologies Inc.
14.4. bioMerieux SA
14.5. Bio-Rad Laboratories Inc.
14.6. DiaSorin S.p.A.
14.7. F. Hoffmann-La Roche Ltd.
14.8. Laboratory Corporation of America Holdings
14.9. Quest Diagnostics Incorporated
14.10. Ortho Clinical Diagnostics
15. Strategic Recommendations16. About the Publisher & Disclaimer

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • Abbott Laboratories
  • AB Sciex Corporation
  • Agilent Technologies Inc.
  • bioMerieux SA
  • Bio-Rad Laboratories Inc.
  • DiaSorin S.p.A.
  • F. Hoffmann-La Roche Ltd.
  • Laboratory Corporation of America Holdings
  • Quest Diagnostics Incorporated
  • Ortho Clinical Diagnostics